<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1320">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668235</url>
  </required_header>
  <id_info>
    <org_study_id>FNC IGZ-1</org_study_id>
    <nct_id>NCT04668235</nct_id>
  </id_info>
  <brief_title>Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)</brief_title>
  <official_title>Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRH Holdngs Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SANTA CASA DE MISERICORDIA DE CAMPOS HOSPITAL (SCMCH), Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF), Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HRH Holdngs Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estimated number of participants: 342 participants with COVID-19 Design: Phase III,&#xD;
      single-center, randomized, double-blind, parallel, placebo-controlled clinical study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      AZVUDINE has therapeutic potential and safety profile for the treatment of patients infected&#xD;
      with SARS-CoV-2.&#xD;
&#xD;
      Goals:&#xD;
&#xD;
      Primary objective • To assess the efficacy and safety of AZVUDINE (FNC) in relation to&#xD;
      placebo, in patients infected with SARS-COV-2 in moderate to severe stage;&#xD;
&#xD;
      Secondary objective&#xD;
&#xD;
      • To evaluate the clinical outcome of the AZVUDINE group (FNC) compared to the placebo group&#xD;
      in patients infected by SARS-COV-2 in moderate to severe stage;&#xD;
&#xD;
      Pharmaceutical form of the experimental medicine:&#xD;
&#xD;
      AZVUDINE 1 mg tablets&#xD;
&#xD;
      Comparators:&#xD;
&#xD;
      AZVUDINE placebo&#xD;
&#xD;
      Statistical planning:&#xD;
&#xD;
      The analyzes will be performed by FAS, PPS and SS and should be stratified by the severity of&#xD;
      the disease (moderate, severe) and age (&lt;60 years, ≥ 60 years), to assess the following&#xD;
      parameters:&#xD;
&#xD;
        -  Progression of the disease (moderate to severe, severe type);&#xD;
&#xD;
        -  Negative viral load conversion rate;&#xD;
&#xD;
        -  Time of negative conversion of viral load;&#xD;
&#xD;
        -  Temperature recovery time;&#xD;
&#xD;
        -  Time necessary to improve diarrhea, myalgia, fatigue, and other symptoms;&#xD;
&#xD;
        -  Time to improve the pulmonary image;&#xD;
&#xD;
        -  Frequency of supplemental oxygenation or non-invasive ventilation;&#xD;
&#xD;
        -  Frequency of AEs;&#xD;
&#xD;
        -  Mortality rate.&#xD;
&#xD;
      All statistical tests will be bilateral tests. If the P value is ≤0.05, it is considered that&#xD;
      there is statistical significance between the difference in the tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of clinical improvement of AZVUDINE (FNC) in COVID-19 treatment</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Rate of participants who reduced at least one level of the Clinical Progression Ordinal Scale category compared to the enrollment status (WHO, Jun/2020)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure outcome rate</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Proportion of participants with clinical cure outcome during the study (viral RNA not detected and clinical conditions for discharge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of body temperature</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time (days) for normalization of body temperature (below 37.6℃ axillary);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement of diarrhea, myalgia fatigue and other symptoms</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time (days) for clinical improvement of diarrhea, myalgia, fatigue, and other symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of inflammatory biochemical markers (Reactive C Protein, erythrocyte sedimentation rate, and Procalcitonin)</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Rate of change in biochemical markers of inflammatory function in relation to the physiological reference intervals between the AZVUDINA and PLACEBO groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of immunological function biochemical markers (IL-6, IgG, IgM, IgA, and complement factor C3 and C4)</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Rate of change in biochemical markers of immunological function in relation to the physiological reference intervals between the AZVUDINA and PLACEBO groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of renal function biochemical markers (serum creatinine and calculated glomerular filtration rate)</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Rate of change in biochemical markers of renal function in relation to the physiological reference intervals between the AZVUDINA and PLACEBO groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of liver function biochemical markers (AST/TGO, ALT/TGP, ALP, GGT, BIL total, and direct BIL)</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Rate of change in biochemical markers of hepatic function in relation to the physiological reference intervals between the AZVUDINA and PLACEBO groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of time to negative conversion of SARS-CoV-2 viral load by RT-PCR</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time (days) to negative conversion of the SARS-CoV-2 viral load between AZVUDINE (FNC) and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the number of cycles for the detection of SARS-CoV-2 viral load by RT-PCR and application of the standard curve for calculating viral load</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>SARS-CoV-2 viral load determination by standard-curve method of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the relationship between the calculated viral load and the clinical evolution of the participants in the experimental group (FNC) and the PLACEBO group</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Rating the relationship between viral load calculated and clinical outcomes of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for improvement of pulmonary condition by imaging exams during treatment</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time (days) for pulmonary image improvement of: (1) Ground glass opacity pattern, (2) mosaic paving, (3) alveolar consolidation, (4) reticular pattern / septal thickening, (5) opaque with inverted halo, (6) pleural / pericardial effusion, (7) fibrosis and / or (8) lymphadenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pulmonary condition by imaging exams during treatment</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Proportion of pulmonary image improvement of: (1) Ground glass opacity pattern, (2) mosaic paving, (3) alveolar consolidation, (4) reticular pattern / septal thickening, (5) opaque with inverted halo, (6) pleural / pericardial effusion, (7) fibrosis and / or (8) lymphadenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for clinical improvement of respiratory signs and symptoms</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time (days) for improvement in respiratory signs and symptoms during treatment (pulmonary rales, cough, sputum, or sore throat)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical improvement of respiratory signs and symptoms</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Rate of improvement in respiratory signs and symptoms during treatment (pulmonary rales, cough, sputum, or sore throat)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for normalization of O2 saturation</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time (days) to normalize O2 saturation (above 95%) between AZVUDINE (FNC) and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate evaluation</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time (days) for respiratory rate normalization ≤24 rpm in room air</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of supplemental oxygenation or non-invasive ventilation</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Frequency of supplemental oxygenation or non-invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Frequency of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of moderate cases that progressed to severe cases</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Proportion of moderate cases that progressed to severe cases requiring care in an intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of hospitalization time</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Length (days) of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of drug interaction events frequency</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Frequency of drug interaction events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of drug interaction events intensity</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Intensity of drug interaction events (1= Mild; 2= Moderate; 3= Severe; 4= Critical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events frequency</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Frequency of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events intensity</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Intensity of adverse events (1= Mild; 2= Moderate; 3= Severe; 4= Critical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of unexpected adverse events frequency</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Frequency of unexpected adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of unexpected adverse events intensity</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Intensity of unexpected adverse events (1= Mild; 2= Moderate; 3= Severe; 4= Critical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of serious adverse events frequency</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Frequency of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of serious adverse events intensity</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Intensity of serious adverse events (1= Mild; 2= Moderate; 3= Severe; 4= Critical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality rate</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Mortality rate during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the tolerability of azvudine in the 5 mg regimen orally QD up to 14 days</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Treatment dropout rate due to AZVUDINE/Placebo intolerance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adherence of azvudine in the 5 mg regimen orally QD up to 14 days</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Medication possession rate, to measure the proportion of administered dose episodes observed in relation to the expected number of doses, until treatment interruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of use of azvudine in the 5 mg regimen orally QD up to 14 days</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Total time (days) of use of AZVUDINE / Placebo intolerance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">342</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Arm AZVUDINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental:&#xD;
AZVUDINE 1mg tablet,&#xD;
Interventions:&#xD;
AZVUDINE 1mg tablet, 5 tablets QD + standard treatment for up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control:&#xD;
AZVUDINE placebo,&#xD;
Interventions:&#xD;
AZVUDINE placebo, 5 tablets QD + standard treatment for up to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZVUDINE</intervention_name>
    <description>5 tablets QD + standard treatment for up to 14 days</description>
    <arm_group_label>Arm AZVUDINE</arm_group_label>
    <other_name>AZVUDINE 1 mg tablets</other_name>
    <other_name>FNC</other_name>
    <other_name>4-amino-1-((2R,3S,4R,5R)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2(1H)-one</other_name>
    <other_name>1-(4-Azido-2-deoxy-2-fluoro-beta-D- arabino Ribo-furanosyl) cytosine, FNC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZVUDINE placebo</intervention_name>
    <description>5 tablets QD + standard treatment for up to 14 days</description>
    <arm_group_label>Arm Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals aged 18 or over, regardless of gender;&#xD;
&#xD;
          2. Patients hospitalized in moderate to severe stages in line with the Ministry of Health&#xD;
             classification;&#xD;
&#xD;
          3. Positive diagnosis for SARS-CoV-2 by molecular amplification of the virus in RT-PCR&#xD;
             diagnosed from a respiratory sample (nasopharynx, oropharyngeal, lower respiratory&#xD;
             tract [eg, sputum]) collected &lt;96 hours before randomization;&#xD;
&#xD;
          4. Time of onset of symptoms and inclusion ≤ 14 days;&#xD;
&#xD;
          5. Internation within 48 hours after inclusion in the study;&#xD;
&#xD;
          6. Follow-up availability during the study period;&#xD;
&#xD;
          7. Voluntary membership to participate in the study and signing the Informed Consent&#xD;
             Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients known or suspected of being sensitive to AZVUDINE or excipients (inactive&#xD;
             ingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone K30,&#xD;
             croscarmellose sodium, magnesium stearate);&#xD;
&#xD;
          2. Patients diagnosed with pneumonia caused by other pathogens;&#xD;
&#xD;
          3. Patients with liver disease (total bilirubin ≥2 times above the normal limit, ALT /&#xD;
             TGP and AST / TGO ≥5 times above the normal limit)&#xD;
&#xD;
          4. Patients with renal failure (glomerular filtration rate ≤60mL / min / 1.73 m2) or are&#xD;
             receiving continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&#xD;
&#xD;
          5. Individuals with malabsorption syndrome, or other conditions that affect&#xD;
             gastrointestinal absorption, and circumstances in which patients need intravenous&#xD;
             nutrition, or cannot take drugs orally or nasogastrically;&#xD;
&#xD;
          6. Pregnant or lactating women, or women with the potential to become pregnant during the&#xD;
             study period and within 6 months after the end of administration;&#xD;
&#xD;
          7. Patients already included in other clinical trials;&#xD;
&#xD;
          8. Patient under treatment for HIV;&#xD;
&#xD;
          9. Patients being treated with other antivirals (eg lopinavir / ritonavir, remdesivir,&#xD;
             umifenovir / arbidol, favipiravir, interferon-α)&#xD;
&#xD;
         10. Patients undergoing treatment with monoclonal antibodies (eg tocilizumab and sarilumab&#xD;
             / kevzara);&#xD;
&#xD;
         11. Patients who are on a clinical treatment plan that includes the concomitant&#xD;
             administration of any other experimental treatment or off-label use of drugs already&#xD;
             on the market (eg hydroxychloroquine sulfate;&#xD;
&#xD;
         12. Patients who require invasive mechanical ventilation or extracorporeal membrane&#xD;
             oxygenation (ECMO) at the time of randomization;&#xD;
&#xD;
         13. Any clinically significant medical condition or medical history that, in the&#xD;
             investigator's opinion, might discourage participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George JM Mota, Pharm BSc</last_name>
    <role>Study Chair</role>
    <affiliation>Galzu Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renato S Martins, MSc, PhD</last_name>
    <phone>+55 22 99998 5248</phone>
    <email>rjrenato@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula GA Cabral, MSc, PhD</last_name>
    <phone>+55 22 98126 6602</phone>
    <email>pgacabral99@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Campos</name>
      <address>
        <city>Campos Dos Goytacazes</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Paula GA Cabral, MSc, PhD</last_name>
      <phone>+55 22 98126 6602</phone>
      <email>pgacabral99@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Renato S Martins, MSc, PhD</last_name>
      <phone>+55 22 99998 5248</phone>
      <email>rjrenato@icloud.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cleber G Silva, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZVUDINE</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>FNC</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

